H2AC16

Across TCGA pan-cancer cohorts, H2AC16 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of H2AC16’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where H2AC16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types H2AC16 is over-expressed in tumor.

LUAD, HNSC, and STAD are the cancer types where H2AC16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in H2AC16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	All	All	+0.698	<.001	10	view →
HNSC	Male	All	+0.681	<.001	10	view →
STAD	All	II,III,IV	+0.902	<.001	8	view →
LIHC	All	II,III,IV	+0.431	<.001	8	view →
LUSC	Male	All	+0.588	<.001	7	view →
COAD	Female	All	+0.533	<.001	7	view →
UCEC	All	All	+0.953	<.001	6	view →
BLCA	Female	All	+0.637	.005	6	view →
BRCA	Female	All	+0.599	<.001	6	view →
KIRP	All	All	+0.123	.004	5	view →
CHOL	All	All	+0.492	.012	2	view →
PRAD	All	All	+0.160	.025	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

H2AC16–LUAD

Open the LUAD breakdown →